This article was originally published in The Gray Sheet
Preliminary clinical trial results show that the firm's human papillomavirus (HPV) cervical cancer screening diagnostic detected "approximately 90% of cervical cancer precursors" compared to the approximately 67% detected by Pap smears, the company announces Jan. 15. Based on 23,000 women in seven countries, the study also found the sensitivity of the HPV screen to range from 81-97% compared to the 37-84% sensitivity range for Pap smears
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.